Publications by authors named "M Lubwama"
Background: We determined the etiology, risk factors, and outcomes associated with bacteremia in patients with hematologic malignancies and febrile neutropenia (FN) at the Uganda Cancer Institute (UCI).
Methods: UCI adult and pediatric inpatients with hematologic malignancies and FN were prospectively enrolled and followed up to determine 30-day mortality. Blood drawn from participants with FN was cultured in the BACTEC 9120 blood culture system.
Article Synopsis
- Hematological cancers like Leukemias and Lymphomas can weaken immune responses, increasing the risk of infections including Human cytomegalovirus (HCMV), particularly in febrile patients.
- A study at the Uganda Cancer Institute found that 66% of 161 febrile hematological cancer patients had been exposed to HCMV, with 14.3% showing signs of active infection.
- The findings suggest that routine HCMV testing in these patients is crucial for timely antiviral treatment to manage infections effectively.
Patients living in low- and middle-income countries (LMICs) shoulder the greatest burden of infections caused by antimicrobial-resistant pathogens. Speedy access to appropriate broad-spectrum antimicrobials significantly improves health outcomes and reduces transmission of antimicrobial-resistant pathogens, but persons living in LMICs have compromised access to these antimicrobials. This article considers how inequities in microbiology diagnostics, antimicrobial access, and antimicrobial affordability influence outcomes for patients infected with antimicrobial-resistant pathogens who live in resource-limited settings.
View Article and Find Full Text PDFPurpose: We determined the phenotypic resistance to third-generation cephalosporins, phenotypic extended spectrum beta-lactamase (ESBL) prevalence, and genotypic prevalence of ESBL-encoding genes and in isolated from hematologic cancer patients with febrile neutropenia and bacteremia at the Uganda Cancer Institute (UCI).
Patients And Methods: Blood cultures from hematologic cancer patients with febrile neutropenia were processed in BACTEC 9120. and .
Background: Leukemia encompasses various subtypes, each with unique characteristics and treatment approaches. The challenge lies in developing targeted therapies that can effectively address the specific genetic mutations or abnormalities associated with each subtype. Some leukemia cases may become resistant to existing treatments over time making them less susceptible to chemotherapy or other standard therapies.
View Article and Find Full Text PDF